



## HDPCR™ SARS CoV-2 Assay Inclusivity Analysis

Last updated: February 11, 2021

ChromaCode diligently performs inclusivity analysis of its HDPCR SARS-CoV-2 Assay, considering new and emerging SARS-CoV-2 sequences as they become available on the GISAID database. The HDPCR SARS-CoV-2 Assay includes the same N1 and N2 oligonucleotide primer and probe sequences for the detection of the SARS-CoV-2 viral RNA and the human RNase P gene used in the CDC 2019–Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel for Emergency Use Only, effective 03/15/2020. The ChromaCode team does extensive *in silico* analysis against all United States sequences deposited into the GISAID on a monthly cadence.

Specifically, in light of recent strain variants highlighted in the media, we can confirm that the ChromaCode HDPCR SARS-CoV-2 Assay is inclusive of the following:

- The United Kingdom Variant, known as 20I/501.V1, VOC 202012/01, or B.1.1.7
- The South African Variant, known as 20H/501Y.V2 or B.1.351
- The Brazil/Japan Variant, known as 20J/501Y.V3 or P.1
- The Denmark/California Variant known as L452R

For a full list of updated *in silico* inclusivity study results, please see the most updated version of the HDPCR SARS-CoV-2 Assay Instructions for Use available at [www.chromacode.com](http://www.chromacode.com), through your instance of ChromaCode Cloud, or on [www.fda.gov](http://www.fda.gov).

### Support

For any questions or clarifications regarding this update, please contact ChromaCode Technical Support.

E-mail: [technical.support@chromacode.com](mailto:technical.support@chromacode.com)

Phone: +1 442-244-4370 ext. 406



ChromaCode, Inc.

2330 Faraday Ave. Suite 100

Carlsbad, CA 92008 USA

442.244.4370 | [chromacode.com](http://chromacode.com)

437971.1